All News

Experts at the 2026 AAD Annual Meeting explained that teledermatology helps dermatologists manage their workload and expand patient access beyond traditional in-person care.

Adjuvant pembrolizumab maintained recurrence-free survival in resected stage IIB/IIC melanoma without increasing new melanoma risk.

Experts reflect on opioid policy impacts, IRA reforms and insulin caps impact drug access, and oncology leaders advance more equitable, integrated cancer care.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

A new analysis projects that millions will lose Medicaid expansion coverage—including many who are working, exempt, or have serious health needs.

Patients with CSU with isolated angioedema tended to have more severe attacks and an inferior response to high-dose antihistamines.

Ruxolitinib cream can meaningfully improve skin repigmentation and QOL for patients with vitiligo, but its full benefit depends on improved patient education, guidance, and support for consistent, long-term use.

Scalp tape strip samples had high concordance with lesion biopsies in patients with alopecia areata.

The LPI/GPR55 axis is a key driver of MAFLD/MASH progression by promoting liver fat accumulation, inflammation, and fibrosis.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis.

A decade after the CDC opioid guidelines, Michael Lynch, MD, examines misapplication, fentanyl’s role, and evolving pain management strategies.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Immunotherapy-related skin adverse events may correlate with improved tumor response and survival, underlining their clinical significance.

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive breast cancer, with manageable safety and consistent benefits across high-risk subgroups.

Population data reveal serious infections drive CLL hospital costs, clarifying morbidity and mortality in the hematologic cancer and its true economic consequences.

This year's meeting in Denver, Colorado, features more than 275 sessions, including 40 new offerings, and a fireside chat with EGOT winner John Legend.

John Barkett, MBA, discusses how health care price transparency can affect both patient out-of-pocket costs and overall health care spending.

New studies show 2024 IRA Medicare drug caps and expanded subsidies cut cost-related nonadherence, especially for those with chronic disease.

Christopher Shade, PhD, shares insights for managed care leaders on oral peptide therapies.

The incidence of very late onset of myasthenia gravis has increased in the past 50 years, which has had implications on prognosis.

Expert insights reveal how to spot inflammation in deeply pigmented skin and use new biologics and melasma therapies to reduce dyspigmentation.

Experts discuss how CDC opioid guidelines reduced prescribing but led to misapplication, affecting patient care and access to pain treatment.

LLMs may improve pediatric clinical decision-making, but gaps in safety, accuracy, and pediatric-specific data remain.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.

Making health care prices public was supposed to cut costs. The reality is more complicated.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.

Medicare Advantage enrollees with advanced cancer had higher hospice use than those with traditional Medicare, highlighting disparities in end-of-life care.